Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART

No abstract is available for this paper.

• Publication year

  2006

• Venue

  AIDS (London)

• Publication date

  2006-02-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.aids.0000199822.49488.50PMID 16439881
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HIV-associated lipodystrophy syndrome.

  2006cited by this paper
• Proliferative, IFNγ and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection

  2006cited by this paper
• Improved Sensitivity of Human Immunodeficiency Virus Type 2 Subtype B Plasma Viral Load Assay

  2005cited by this paper
• Fenofibrate: metabolic and pleiotropic effects.

  2005cited by this paper
• Pleiotropic effects of statins.

  2005cited by this paper
• Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis.

  2005cited by this paper
• Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.

  2005cited by this paper
• Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.

  2005cited by this paper
• Diagnosing chest pain.

  2005cited by this paper
• Journal of Negative Results in Biomedicine Open Access the "statinth" Wonder of the World: a Panacea for All Illnesses or a Bubble about to Burst

  2005cited by this paper
• The Effect of Statins on HIV Rebound and Blips

  2005cited by this paper
• Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study

  2005cited by this paper
• Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia

  2005cited by this paper
• Statins and HIV: beyond the metabolic and cardiovascular benefit.

  2005cited by this paper
• Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors

  2005cited by this paper
• Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

  2004cited by this paper
• HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1

  2004cited by this paper
• Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis

  2004cited by this paper
• Statins Inhibit HIV-1 Infection by Down-regulating Rho Activity

  2004cited by this paper
• Highly active antiretroviral therapy and viral response in HIV type 2 infection.

  2004cited by this paper
• Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.

  2004cited by this paper
• SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

  2004cited by this paper
• Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease1

  2004cited by this paper
• Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

  2004cited by this paper
• Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)

  2004cited by this paper
• Polymorphism and Drug-Selected Mutations in the Protease Gene of Human Immunodeficiency Virus Type 2 from Patients Living in Southern France

  2004cited by this paper
• Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study

  2003cited by this paper
• Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people.

  2003cited by this paper
• Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort

  2003cited by this paper
• Attenuated T-Lymphocyte Response to HIV Therapy in Individuals Receiving HMG-CoA Reductase Inhibitors

  2003cited by this paper
• Antiretroviral therapy in HIV‐2‐infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire

  2003cited by this paper
• Antiretroviral therapy in HIV-2-infected patients

  2003cited by this paper
• Rapid progression of CD4 cell decline and subsequent response to salvage therapy in HIV-2 infection.

  2002influential reference
• Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57

  2002cited by this paper
• Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

  2002cited by this paper
• Relationship of serum ferritin with cardiovascular risk factors and inflammation in young men and women.

  2002cited by this paper
• PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis

  2002cited by this paper
• Comparison between HIV‐ and CMV‐specific T cell responses in long‐term HIV infected donors

  2002cited by this paper
• The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.

  2001cited by this paper
• Antiretroviral therapy for HIV-2 infected patients.

  2001cited by this paper
• Quantification of Proviral Load of Human Immunodeficiency Virus Type 2 Subtypes A and B Using Real-Time PCR

  2001cited by this paper
• Pleiotropic effects of statins

  2000cited by this paper
• Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution.

  2000cited by this paper
• Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection.

  2000cited by this paper
• Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

  2000cited by this paper
• HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

  2000cited by this paper
• HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women.

  1999cited by this paper
• HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.

  1999cited by this paper
• Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques

  1999cited by this paper
• Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

  1999cited by this paper
• Relation between iron stores and non-insulin dependent diabetes in men: case-control study

  1998cited by this paper
• Serum Ferritin as a Component of the Insulin Resistance Syndrome

  1998cited by this paper
• Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease

  1998cited by this paper
• Kinetics of Antiviral Activity by Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes (CTL) and Rapid Selection of CTL Escape Virus In Vitro

  1998cited by this paper
• Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.

  1998cited by this paper
• Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors.

  1997cited by this paper
• Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load.

  1996cited by this paper
• Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya.

  1996cited by this paper
• Novel, Cross-Restricted, Conserved, and Immunodominant Cytotoxic T Lymphocyte Epitopes in Slow Progressors in HIV Type 1 Infection

  1996cited by this paper
• Influence of combinations of human major histocompatibility complex genes on the course of HIV–1 infection

  1996cited by this paper
• Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP).

  1995cited by this paper
• Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

  1994cited by this paper
• Cellular and plasma viral load in patients infected with HIV‐2

  1993cited by this paper
• HIV-2 infection in the United States.

  1989cited by this paper
• Virus-Specific CD 8 + Cytotoxic T-Lymphocyte Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection

  year unknowncited by this paper

• Chemistry and Biology of Ferritin

  2021cites this paper
• Association of immune recovery with hyperlipidaemia and apolipoprotein gene polymorphisms following highly active antiretroviral therapy in a cohort of Chinese HIV patients

  2016cites this paper
• School of Health Systems and Public Health Management of dyslipidemia in HIV infected patients on combined antiretroviral therapy: effects of intervention

  2015cites this paper
• Management of dyslipidemia in HIV infected patients on combined antiretroviral therapy : effects of intervention

  2015influential citation
• Persistent immune activation in chronic HIV infection: do any interventions work?

  2013cites this paper
• RandomizedclinicaltrialoflovastatininHIV-infected, HAART na€ive patients (NCT00721305)

  2012cites this paper
• Randomized clinical trial of lovastatin in HIV-infected, HAART naïve patients (NCT00721305).

  2012cites this paper
• Randomized clinical trial of lovastatin inHIV-infected, HAART na€ıve patients (NCT00721305)

  2012cites this paper
• Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study

  2011cites this paper
• Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance.

  2010cites this paper
• Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial

  2009cites this paper
• Potential New Therapeutic Agents: Effects on HIV Replication and Viral Escape

  2009cites this paper
• Statins for the prevention and treatment of infections: a systematic review and meta-analysis.

  2009cites this paper
• Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.

  2008cites this paper
• Dyslipidemia in HIV infection

  2006cites this paper